Pre-Treatment HBV Activation Modulates Circulating Immune Markers in Hepatocellular Carcinoma Patients Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs.

Cancer Manag Res · 2026 · PMC12927724 · PMID 41737138

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

did not reach statistical significanceP = 0.058so close (0.05 < p ≤ 0.1)

However, in the non-objective response (Non-OR) group, a trend toward worse survival was observed in patients with active HBV infection compared to those with inactive HBV infection, although the difference did not reach statistical significance ( P = 0.058, Figure 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.